Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
Subscribe To Our Newsletter & Stay Updated
